Investor relations

Why invest in NanoEcho?

We are addressing an urgent medical need

The global market is expected to grow by 50 percent until 2030

More and more countries are introducing systematic screening to reduce rectal cancer mortality

Attractive Market dynamic with low entry barriers

Reports

Annual Report 2020

Annual Report 2019

Owners

10 largest owners as of 2021-03-31

Ownership structure

CARDEON AB (PUBL)

ÅLANDSBANKEN I ÄGARES STÄLLE

NORDNET PENSIONSFÖRSÄKRING AB

QUIQ DISTRIBUTION HOLDING AB

KHAYYAMI, MASOUD

JANSSON, TOMAS

CLOUDO AB

MK CAPITAL INVEST AB

KOGAI INVEST AB

MAXISTANS AB

OTHERS

In total

Stocks

91.409.098

51.150.000

33.065.660

16.666.667

10.766.667

10.000.000

7.192.016

6.566.667

5.900.000

4.016.66

63.897.886

300.631.327

PCT %

30,41

17,01

5,54

3,58

3,33

2,39

2,18

1,96

1,34

21,26

100

Financial calendar

Annual Report 2020

Quarterly Report 1, Q1

Annual General Meeting

Quarterly Report 2, Q2

Kvartalsrapport 3, Q3

Quarterly Report 4, Q4 
(Year-end report)

2021-04-06

2021-04-28

2021-05-12

2021-08-19

2021-10-28

2022-02-16

Annual General Meeting

General meeting notice

Notice of AGM 120521

General meeting minutes

Minutes of EGM 210226

Minutes of AGM 200618

Minutes of AGM 190628

Annexes

The Board of Directors’ proposal for authorization

The Board of Directors’ proposal for association change

The Board of Directors’ proposal for Nomination Committee instructions

Prospekt/Erbjudande

Certified adviser

First North supplies infrastructure for trading and distribution of share information. In order to be admitted to trading on First North, a company must appoint a Certified Adviser that will guide the company through the application process and ensure that the company lives up to and continuously complies with the regulations. The Certified Adviser ensures that the company meets the admission criteria and the continuing obligations related to having its share admitted to trading on First North. In addition, the Certified Adviser monitors that the company abides by the rules on an ongoing basis and reports any irregularities to the marketplace without delay.

G&W Fondkommission is NanoEcho AB’s Certified Adviser.

G&W Fondkommission
Kungsgatan 3
111 43 Stockholm, Sweden
http://www.gwkapital.se

References

General information about the magnetomotive ultrasound technology

Sjöstrand S, Evertsson M, Jansson T, “Magnetomotive Ultrasound Imaging Systems: Basic Principles and First Applications”, Ultrasound Med Biol, Volume 46, (2020), Issue 10, Pages 2636-2650
J. Oh, M.D. Feldman, J. Kim, C. Condit, S. Emelianov, T.E. Milner “Detection of magnetic nanoparticles in tissue using magneto-motive ultrasound”, Nanotechnology, 17 (2006), pp. 4183-4190
Evertsson, Maria, et al. “Combined Magnetomotive ultrasound, PET/CT, and MR imaging of 68 Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo.” Scientific reports 7.1 (2017): 1-9
Maria Evertsson, Magnus Cinthio, Sarah Fredriksson, Pontus Kjellman, Rene in’t Zandt, Hans W. Persson, Tomas Jansson: Multimodal detection of iron oxide nanoparticles in rat lymph nodes using Magnetomotive ultrasound imaging and Magnetic Resonance Imaging, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol 61, no.8, pp 1276-1283, 2014.

Järnoxidbas Iron-oxide-based nanoparticles erade nanopartiklar

L. Johnson et al; Deposition of Superparamagnetic Iron-Oxide Nanoparticles in Axillary Sentinel Lymph Nodes Following Subcutaneous Injection, Histopathology 62 (2013), 481–486
Ghilli, M., et al. “The superparamagnetic iron oxide tracer: a valid alternative in sentinel node biopsy for breast cancer treatment.” European journal of cancer care 26.4 (2017): e12385.
R. Qiao, C. Yang, M. Gao ”Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications”, J Mat Chem, 19 (2009), pp. 6274-6293

The need within rectal cancer

Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. ”Global patterns and trends in colorectal cancer incidence and mortality” Gut. 01 april 2017;66(4):683–91
Thorlacius H, Toth E ” Screening för kolorektal cancer – evidensläge, metoder och utmaningar” Läkartidningen vol 115
Thorlacius H., Uedo N., and Toth E. Endoscopic submucosal dissection (ESD) is a minimal invasive method for removal large colorectal tumours. Läkartidningen, 2012;45:2019-2023.
Srisajjakul S, Prapaisilp P, Bangchokdee S. Pitfalls in MRI of rectal cancer: What radiologists need to know and avoid. Clinical imaging. 2017;50:130-40.
Siddiqui MRS, Simillis C, Hunter C, Chand M, Bhoday J, Garant A, et al. A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. British journal of cancer. 2017.
de Jong EA, ten Berge JC, Dwarkasing RS, Rijkers AP, van Eijck CH. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis. Surgery. 2016;159(3):688-99.
de Jong EA, Ten Berge JC, Dwarkasing RS, Rijkers AP, van Eijck CH. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis. Surgery. 2015.
Rönnow CF, Arthursson V, Toth E, Krarup PM, Syk I, Thorlacius H. “Lymphovascular Infiltration, Not Depth of Invasion, is the Critical Risk Factor of Metastases in Early Colorectal Cancer: Retrospective Population-based Cohort Study on Prospectively Collected Data, Including Validation” Annals of Surgery. March 13, 2020

Potential future applications

Evertsson, Maria, et al. “Combined Magnetomotive ultrasound, PET/CT, and MR imaging of 68 Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo.” Scientific reports 7.1 (2017): 1-9
M. O’Donnell, ”Magnetic nanoparticles as contrast agents for molecular imaging in medicine”, Physica C, 548 (2018), pp. 103-106
B.E. Levy, M.M. Hossain, J.M. Sierchio, D. Thapa, C.M. Gallippi, A.L. Oldenburg, ”Effect of model thrombus volume and elastic modulus on magnetomotive ultrasound signal under pulsatile flow”, IEEE Trans Ultrason Ferroelectr Freq Control, 65 (2018), pp. 1380-1388
M. Fink, H. Ermert, S. Lyer, C. Alexiou, ”Influence of naturally occurring tissue movements on magnetomotive ultrasound detection of iron oxide nanoparticles for magnetic drug targeting”, 2017 IEEE International Ultrasonics Symposium (IUS)
Santiesteban DY, Kubelick K, Dhada KS, Dumani D, Suggs L, Emelianov S, ” Monitoring/Imaging and Regenerative Agents for Enhancing Tissue Engineering Characterization and Therapies”, Annals of Biomedical Engineering, 21 Dec 2015, 44(3):750-772

The share

NanoEcho is a VPC company, and its shares are registered in electronic form. The share book is kept by Euroclear Sweden AB. All shares belong to the same class. They are equally entitled to a share of the company’s assets and profits and carry the same voting rights. All shares are issued and fully paid.

Number of shares: 300,631,327
ISIN code: SE0013775566

Corporate governance

The Articles of Association stipulate that the Board of Directors shall consist of between three (3) and eight (8) members and no more than two (2) alternates. Board members and alternates are elected by the Annual General Meeting. The duties and responsibilities of the Board of Directors shall apply until the end of the next Annual General Meeting, which is planned to take place on nn nn, 2021. The Board of Directors and all members of the board can be reached at the company’s head office at Gasverksgatan 1, 222 29 Lund, Sweden. The work of the Board of Directors is governed by the Companies Act, the Articles of Association and the rules of procedure as adopted by the Board of Directors.

Articles of Association

Articles of Association adopted by the Annual General Meeting 210226

Contact

Dr. Linda Persson
CEO
E-mail: lp@nanoecho.se

Annika Andersson
CCO
E-mail: aan@nanoecho.se